Journal of Thoracic Oncology最新文献

{"title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy","authors":"Natasha B. Leighl MD, MMSc ,&nbsp;Luis Paz-Ares MD ,&nbsp;Delvys Rodriguez Abreu MD, PhD ,&nbsp;Rina Hui MBBS, PhD ,&nbsp;Sofia Baka MD, MSc, PhD ,&nbsp;Frédéric Bigot MD ,&nbsp;Makoto Nishio MD, PhD ,&nbsp;Alexey Smolin MD ,&nbsp;Samreen Ahmed MD ,&nbsp;Adam J. Schoenfeld MD ,&nbsp;Sameh Daher MD ,&nbsp;Diego L. Cortinovis MD ,&nbsp;Vincenzo Di Noia MD ,&nbsp;Helena Linardou MD ,&nbsp;Justin F. Gainor MD ,&nbsp;Corina Dutcus MD ,&nbsp;Chinyere E. Okpara PhD ,&nbsp;Xuan Deng PhD ,&nbsp;Debra Kush MBA, BSN ,&nbsp;Ashwini Arunachalam MD ,&nbsp;Byoung Chul Cho MD, PhD","doi":"10.1016/j.jtho.2025.05.020","DOIUrl":"10.1016/j.jtho.2025.05.020","url":null,"abstract":"<div><h3>Background</h3><div>LEAP-008 (NCT03976375) was an open-label, randomized, phase 3 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic NSCLC that progressed on anti‒programmed cell death protein 1 or anti‒programmed cell death ligand 1 therapy and platinum-containing chemotherapy.</div></div><div><h3>Methods</h3><div>Participants were randomized 4:4:1 to once-daily lenvatinib 20 mg plus pembrolizumab 200 mg every 3 weeks (maximum 35 cycles), docetaxel 75 mg/m² every 3 weeks, or once-daily lenvatinib 24 mg. Primary end points were overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 by central review. The superiority of lenvatinib plus pembrolizumab versus docetaxel was assessed at interim analysis 2 for PFS and final analysis for OS.</div></div><div><h3>Results</h3><div>Participants (N = 422) were randomized to lenvatinib plus pembrolizumab (n = 185), docetaxel (n = 189), or lenvatinib monotherapy (n = 48). The median (95% confidence interval [CI]) PFS was 5.6 (4.2‒6.5) months with lenvatinib plus pembrolizumab and 4.2 (3.2‒5.2) months with docetaxel (hazard ratio, 0.89 [95% CI: 0.70‒1.12]; <em>p</em> = 0.164). The median (95% CI) OS was 11.3 (9.4‒13.2) versus 12.0 (9.6‒13.7) months (hazard ratio, 0.98 [95% CI: 0.78‒1.23]; <em>p</em> = 0.434). Rates of treatment-related adverse events were 91.7%, 91.0%, and 89.4% with lenvatinib plus pembrolizumab, docetaxel, and lenvatinib, respectively; the rates of grade 3 to 5 treatment-related adverse events were 59.7%, 48.6%, and 57.4%. Health-related quality of life scores were similar between treatment arms.</div></div><div><h3>Conclusion</h3><div>Lenvatinib plus pembrolizumab did not improve efficacy versus docetaxel in participants with stage IV NSCLC that progressed on anti‒programmed cell death protein 1 or anti–programmed cell death ligand 1 therapy and platinum-containing chemotherapy. There were no unexpected safety signals. More effective therapies are needed for this patient population.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1489-1504"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor–Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations","authors":"Zhuoran Yao MD ,&nbsp;Min Tang MD ,&nbsp;Ying Jin MS ,&nbsp;Jie Ruan MD ,&nbsp;Yong Hu MD ,&nbsp;Hua Xie MS ,&nbsp;Zhenlei Wang PhD ,&nbsp;Lisha Fu BSc ,&nbsp;Xing Huang MS ,&nbsp;Xiaojuan Zhou MD ,&nbsp;Bingwen Zou MD ,&nbsp;Geofrrey Liu MD ,&nbsp;Li Zheng MD ,&nbsp;You Lu MD","doi":"10.1016/j.jtho.2025.05.017","DOIUrl":"10.1016/j.jtho.2025.05.017","url":null,"abstract":"<div><h3>Introduction</h3><div>Lorlatinib is the preferred first-line treatment for advanced <em>ALK</em>+ (<em>ALK</em>+) NSCLC on the basis of the 5-year CROWN update. However, the effects of lorlatinib on the fetus and neonate remain unknown.</div></div><div><h3>Methods</h3><div>We report the first case of a patient with metastatic <em>ALK+</em> NSCLC who became pregnant during treatment with lorlatinib. A literature review was performed to identify all previously reported pregnancies of <em>ALK</em>+ NSCLC. The collection, determination, and analysis of lorlatinib pharmacokinetics and mass spectroscopy imaging of lorlatinib are both performed.</div></div><div><h3>Results</h3><div>A 33-year-old pregnant woman with a 7-year history of <em>ALK+</em> metastatic NSCLC was admitted to the hospital with brain metastases recurrence at 20 weeks of gestation. She self-discontinued lorlatinib at 4 weeks of gestation after long-term disease control on a reduced dose. According to the patient’s preference, low-dose lorlatinib was reintroduced at 20 weeks, with successful tumor control and normal fetal growth. At 20-month follow-up postpartum, the mother maintained intracranial and systemic remission, and no congenital abnormalities were observed in the baby. Pharmacokinetic analyses and mass spectroscopy imaging peridelivery confirmed the placental transfer of lorlatinib.</div></div><div><h3>Conclusions</h3><div>The case highlights both the potential safety and safety concerns with the use of lorlatinib during pregnancy, along with the unique nature of central nervous system–dominant <em>ALK+</em> NSCLC, and the potential clinical utility of dose-reduced lorlatinib.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1531-1537"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","authors":"Byoung Chul Cho MD, PhD ,&nbsp;Weimin Li MD ,&nbsp;Alexander I. Spira MD, PhD ,&nbsp;Maxwell Sauder MD ,&nbsp;Jill Feldman MA ,&nbsp;Farastuk Bozorgmehr MD ,&nbsp;Milena Mak MD ,&nbsp;Janellen Smith MD ,&nbsp;Pei Jye Voon MD ,&nbsp;Baogang Liu MD ,&nbsp;Panwen Tian MD ,&nbsp;Jiunn-Liang Tan MD ,&nbsp;Cheng-Ta Yang MD ,&nbsp;Jin-Yuan Shih MD, PhD ,&nbsp;Nuri Karadurmus MD ,&nbsp;Juan Esteban Cundom MD ,&nbsp;Glaucio Bertollo MD ,&nbsp;Irfan Cicin MD ,&nbsp;Jorge Nieva MD ,&nbsp;Ana Laura Ortega-Granados MD ,&nbsp;Nicolas Girard MD, PhD","doi":"10.1016/j.jtho.2025.07.117","DOIUrl":"10.1016/j.jtho.2025.07.117","url":null,"abstract":"<div><h3>Introduction</h3><div>Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, <em>EGFR</em>-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.</div></div><div><h3>Methods</h3><div>In the phase 2 COCOON study (NCT06120140), participants with previously untreated, <em>EGFR</em>-mutant, locally advanced or metastatic NSCLC received intravenous amivantamab plus oral lazertinib and were randomized 1:1 to enhanced dermatologic management (COCOON DM) or standard of care (SoC DM) per local guidelines. COCOON DM included oral doxycycline or minocycline (100 mg twice daily; weeks 1–12), clindamycin 1% (on scalp daily; weeks 13–52), chlorhexidine 4% (on fingernails and toenails daily), and ceramide-based moisturizer (on body and face at least daily). Primary end point was incidence of grade 2 or higher dermatologic AEs of interest (DAEIs) by week 12.</div></div><div><h3>Results</h3><div>In total, 201 participants were randomized (99 to COCOON DM and 102 to SoC DM). At a median follow-up of 7.1 months, COCOON DM demonstrated significant reduction in the primary end point versus SoC DM (42% versus 75%; OR, 0.24; 95% confidence interval, 0.13–0.45; <em>p</em> &lt; 0.0001). By week 12, the largest benefit with COCOON DM was observed in DAEIs involving the face and body (excludes paronychia; 26% versus 60%; <em>p</em> &lt; 0.0001) and DAEIs involving the scalp (10% versus 26%; <em>p</em> = 0.0049). This benefit was maintained at 6 months, with significant reductions of DAEIs involving face, body, and scalp (excluding paronychia). Patient-reported outcomes favored COCOON DM, indicating reduced impact of dermatologic symptoms on QoL.</div></div><div><h3>Conclusion</h3><div>An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1517-1530"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint' [Journal of Thoracic Oncology Volume 19 Issue 6 (2024) 858-861].","authors":"Paula Ugalde Figueroa, Valérie Lacroix, Paul E Van Schil","doi":"10.1016/j.jtho.2025.09.009","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.09.009","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups”","authors":"Matthew G. Krebs MD, PhD,&nbsp;Byoung Chul Cho MD, PhD,&nbsp;Priya Kim MD,&nbsp;Alexander I. Spira MD, PhD,&nbsp;Natasha B. Leighl MD","doi":"10.1016/j.jtho.2025.07.003","DOIUrl":"10.1016/j.jtho.2025.07.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages e109-e110"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00997-9","DOIUrl":"10.1016/S1556-0864(25)00997-9","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Page A3"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco News Update — From the IASLC Tobacco Control Committee","authors":"","doi":"10.1016/j.jtho.2025.08.013","DOIUrl":"10.1016/j.jtho.2025.08.013","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1352-1355"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic","authors":"Jarushka Naidoo M.B.B.S., MHS ,&nbsp;Abesh Niroula MD ,&nbsp;Dipesh Uprety MD ,&nbsp;Matthew Smeltzer PhD ,&nbsp;Nicole Geissen DO ,&nbsp;Raymond U. Osarogiagbon M.B.B.S. ,&nbsp;Mari Mino-Kenudson MD ,&nbsp;Yasushi Yatabe MD ,&nbsp;Kristin Higgins MD ,&nbsp;Aakash Desai M.B.B.S. ,&nbsp;Karen L. Reckamp MD ,&nbsp;Jessica Jiyeong Lin MD ,&nbsp;Stephen V. Liu MD ,&nbsp;Fiona Hegi-Johnson Franzcr M.B.B.S., PhD ,&nbsp;Nagashree Seetharamu MD, M.B.B.S. ,&nbsp;David Harpole MD ,&nbsp;Martin J. Edelman MD ,&nbsp;IASLC Communications Committee","doi":"10.1016/j.jtho.2025.06.028","DOIUrl":"10.1016/j.jtho.2025.06.028","url":null,"abstract":"<div><div>In the past 50 years, we have seen a dramatic evolution in thoracic oncology. We have gone from a time of limited understanding of the biology of lung cancer, no demonstrated benefits for screening, and marginal benefits from therapy to an era of molecular profiling, survival benefits from low-dose computed tomography screening, and a steadily expanding list of therapeutic options. Coupled with these advances have been substantial improvements in approaches related to supportive care and end of life. In this state-of-the-art article, the Communications Committee of the International Association for the Study of Lung Cancer presents a comprehensive summary of how some of the major questions in lung cancer were addressed during the last 50 years: from prevention to staging, screening, diagnostics, therapeutics, and supportive care. This is intended to serve as a “survival guide” for new standards in lung cancer care aimed at clinicians and other interested stakeholders, which places these current standards of care in the context of progress in the last 50 years.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1392-1422"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Announcements","authors":"","doi":"10.1016/S1556-0864(25)00999-2","DOIUrl":"10.1016/S1556-0864(25)00999-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Page A4"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reading Between the Lines: Circulating Tumor DNA Dynamics Illuminate Immunotherapy Outcomes in Lung Squamous Cell Carcinoma","authors":"Eloísa Jantus-Lewintre PhD ,&nbsp;Ana Patiño-García PhD ,&nbsp;Angel Díaz-Lagares PhD","doi":"10.1016/j.jtho.2025.07.011","DOIUrl":"10.1016/j.jtho.2025.07.011","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 10","pages":"Pages 1362-1365"},"PeriodicalIF":20.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}